Futura Medical is at exciting juncture, with the second pivotal trial of Eroxon® (erectile dysfunction) due to start in Q4 2017 and licensing discussions ongoing for multiple products, including Eroxon® and topical pain relief products TPR100 (diclofenac) and TIB200 (ibuporofen). Longer term, we believe that the OTC market for Eroxon® could represent a significant opportunity, over and above our current prescription-only estimates. We reiterate our positive stance and unchanged 93p/share intrins ....
12 Apr 2017
N+1 Singer - Futura Medical - Multiple licensing discussions underway
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Futura Medical - Multiple licensing discussions underway
Futura Medical plc (FUM:LON) | 35.5 -0.4 (-2.7%) | Mkt Cap: 107.0m
- Published:
12 Apr 2017 -
Author:
Dr Jens Lindqvist -
Pages:
4
Futura Medical is at exciting juncture, with the second pivotal trial of Eroxon® (erectile dysfunction) due to start in Q4 2017 and licensing discussions ongoing for multiple products, including Eroxon® and topical pain relief products TPR100 (diclofenac) and TIB200 (ibuporofen). Longer term, we believe that the OTC market for Eroxon® could represent a significant opportunity, over and above our current prescription-only estimates. We reiterate our positive stance and unchanged 93p/share intrins ....